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SUMMARY 
Prolyl endopeptidase (PEP: [E.C.3.4.21.26]) is a widely distributed serine 
peptidase that cleaves a variety of oligopeptides in the brain and 
peripheral tissues. Y-29794 ((2-(8-dimethylaminooctylthio)-6-isopropyl-3- 
pyridyl-2-thienyl ketone) is a potent competitive reversible inhibitor of this 
enzyme. In order to study the biodistribution of PEP in vivu we have 
synthesized (N-" C]methyl)Y-29794, by [11C]alkylation of the N- 
desmethyl precursor. The radiotracer was purified by silica gel Sep-Pak 
and was obtained in 10-17% yields (EOB: synthesis times shorter than 45 
min) with >98% radiochemical purities and specific activities >550 Ci/mmol 
(EOS). 
Key-words: (N-[11C]methyl)Y-29794, prolyl endopeptidase, protease 
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INTRODUCTION 
Prolyl endopeptidase (PEP: [E.C.3.4.21.26]) is a cytosolic serine protease that 
hydrolyzes peptide bonds at the carboxylic end of proline and alanine residues of 
oligopeptidesll2. It is a widely distributed enzyme found in many species including 
manfl2, and is located in a variety of tissues such as uterus, liver, kidney and brainl-3. 
PEP degrades a variety of oligopeptides including substance P, oxytoxin, angiotensin I I ,  
vasopressin and TRH1-2, and more recently, it has been implicated in the processing of 
the amyloid precursor protein (APP)435. 
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A possible role of PEP in the biochemical mechanism of memory has been 
suggested by in vivo studies, where PEP inhibitors were shown to produce anti-amnesic 
effects in rodents previously treated with scopolamine6-8. Y-29794 (248- 
dimethylaminooctylthio)-6-isopropyl-3-pyridyl-2-thienyl ketone)g (Figure 1 ) is one of the 
most potent competitive reversible inhibitors of PEP (IC504 nM) and has been shown, in 
ex vivo experiments, to cross the blood brain barrier and inhibit brain PEP in rodentsg. 
The study of biodistribution and activity of brain proteases using radiolabeled 
enzyme inhibitors and Positron Emission Tomography (PET) might provide a new and 
important approach to the evaluation of the roles of peptides and protein degradative 
processes in normal and diseased human brain. With this goal in mind, we report here the 
synthesis of (N-[11C]methyl)Y-29794. The results from the biological experiments will be 
presented elsewhere. 
The typical procedure for the synthesis of (N-[11C]methyl)Y-29794 12' is shown in 
Figure 1. A solution of desmethylY-29794 tosylate 1 in dirnethylformamide was 
neutralized with triethylamine and the free base was reacted with no-camer-added 
[I TCICH31 (5 min at 85 OC). The desired product 2 was purified by silica gel 
chromatography, using the following procedure: the reaction mixture was adsorbed onto 
the first of two serial dry silica gel Sep-Paks which were washed with ethyl acetate to 
remove unreacted [11C]CH31 and DMF. The product 2 was then selectively eluted from 
the silica gel using ethyl acetatehriethylamine (99/1); under these conditions, unreacted 
precursor is not eluted from the silica gel (see below). The organic solvents were 
evaporated using a stream of nitrogen at 120 OC.  Because Y29794 is a very lipophilic 
compound (calculated IogP-6.1), formulation required collection of the solvent fraction 
carrying the radiotracer in a vial previously washed with aqueous hydrochloric acid, in 
order to protonate the tertiary amine, followed by addition of sterile water and adjustment 
of the solution to slightly acidic pH with 1 N sodium bicarbonate. Syntheses times, 
including the formulation step, were typically less than 45 min from end-of-bombardmew 
(EOB), radiochemical yields ranged between 10-17% (decay corrected to EOB) and 
radiochemical purities were >98% as determined by HPLC (reaction conditions and yields 
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have not been optimized). Specific activities were >550 Ci/mmol at end of synthesis 
(EOS). Isolated 2 was shown to co-elute with authentic Y-29794 by analytical HPLC. 
Figure 1, Synthesis of (N-["C]methyl)Y-29794 
1 2 
DesmethylY-29794 tosylate (N-[' ' Clmet hyl)Y-29794 
10-17% (EOB), 4 5  min 
>98% radiochemical purity 
>550 Ciimmol (EOS) 
The purification of 2 described here was developed to specifically avoid the use of 
HPLC. We have found that small disposable chromatographic columns (custom-packed 
columns or Sep-Paks) can provide effective separation of radiopharmaceutical products 
from chemical and radiochemical impurities, and this technique has been used in 
preparations of such radiotracers as [ I f  C]flumazenil10, I l sqGBR 1290913, and 
[I 1C]raclopride (unpublished results). In the development of this technique for purification 
of (N-[l 1C]methyl)Y-29794, a solution of 2 mg of desmethylY28794 tosylate 1 (twice the 
amount used in the radiochemical synthesis) and triethyiamine in dimethylformamide was 
loaded onto two dry serial silica gel Sep-Paks which were eluted sequentially with ethyl 
acetate (this was discarded) and ethyl acetate/triethylamine (99/1) solution; volumes 
were identical to those utilized in the radiochemical synthesis. The acetatehriethylamine 
eluant was evaporated using a gentle stream of nitrogen (in order to avoid interference of 
ethyl acetate with the UV absorption of 1) and the residue was dissolved in acetonitrile 
(I0 mL). The UV absorption of this solution was then measured (Perkin Elmer Larnda 6 
UVNlS spectrophotometer) and compared to the absorptions of known concentrations of 
desmethylY-29794 tosylate solutions in acetonitrile. The absorption of the solution (31 8 
nm, Amax of desmethylY-29794) was near the limits of detection and corresponded to a 
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concentration of 0.33 pg/mL of precursor, demonstrating that the silica gel Sep-Paks were 
efficient at removing ~ 9 9 %  of precursor loaded onto the columns. Also, the amount of 1 
eluted from the silica gel was unaffected by the rate of passage of solvents through the 
Sep-Paks. 
In conclusion we have synthesized (N-[11C]methyI)Y-29794, including a simple 
purification procedure that does not require HPLC, and have obtained the radiotracer in 
high specific activities and sufficient yields to undertake animal studies. 
EXPERIMENTAL 
Materials and methods. Triethylamine and dimethyl formamide were purchased 
from Aldrich Chemical Company and were used without further purification. All solvents 
used were high pressure liquid chromatography grade. The Sep-Paks used were silica 
cartridges purchased from Waters Associates. [1 1 CICarbon dioxide (approx. 2500 mCi), 
produced by proton irradiation of a nitrogen gas target at 20 pA for 25 min, was converted 
to [11C]methyl iodide by lithium aluminum hydride reduction followed by treatment with 
hydroiodic acid. All radiosyntheses were done in small glass vessels (1 mL) in a remote 
apparatus which was manipulated from outside the hot cell. Determination of specific 
activities and chemical and radiochemical purities were done using analytical HPLC (0.46 
x25 cm, silica gel column, UV 320 nm, CH2C12: EtOAC: Et3N 80:18:2, 1 mUmin, Rt of 2 
=4.7 min). 
Synthesis of (N-[11C]methyl)Y-29794. A glass reaction vessel containing a 
solution of desmethylY-29794 tosylate (1 mg, 1.7 pmol) and triethylamine (5 pL, 69 pmolj 
in 250 pL of dimethylformamide was placed in a remote apparatus, and all subsequent 
steps were done from outside of the closed hot cell. The reaction vessel was cooled to 
approximately -30 OC, and [11C]CH31 (carried by a stream of nitrogen) bubbled into the 
vessel. The reaction vessel was then closed and heated at 85 OC for 5 min. After cooling 
to room temperature, the mixture was loaded onto two dry silica gel Sep-Paks, connected 
in series. The reaction vial was washed with 1 mL of ethyl acetate which was also loaded 
on the Sep-Paks. The Sep-Paks were washed with ethyl acetate (20 mL) which was 
discarded, and (N-[l1C]methyI)Y-29794 was then eluted using 10 mL of a solution of ethyl 
acetateltriethylarnine (9911). The eluent was collected in a vial previously washed with 1 N 
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hydrochloric acid (but not dried), and the solvent was removed with a stream of nitrogen 
at 120 OC. To the isolated (N-[11C]methyl)Y-29794 was first added 1.5 mL of 0.3N 
hydrochloric acid followed by addition of 1.2 mL water and approximately 350 pL of 1 .O N 
sodium bicarbonate solution, until the solution became slightly acidic (pH approx. 6.5). 
The radiochemical yield was 31.8 mCi (17%, EOB) in a synthesis of 45 min. The 
radiochemical purity was >98% and the specific activity was 638 Ci/mmol at EOS. 
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